Navigation Links
ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results
Date:3/3/2009

very; and ExonHit takes the lead in the breast cancer program (EHT Dx11) using the same platform. Results are expected in Q4 2009.

EHT Dx11 could become the first blood-based diagnostic test providing an alternative to mammography for younger women whose sensitivity to mammography is low, or for women who decide not to undergo mammography screening. EHT Dx12 has the potential to offer an alternative to very uncomfortable colonoscopy. EHT Dx13 may become the first blood based diagnostic test with a significantly increased accuracy compared to the widely used PSA (prostate specific antigen) test.

- Therapeutics

EHT 0202, ExonHit's lead candidate in Alzheimer's disease, is currently in Phase IIa testing. Patient enrolment was completed at the end of February and study results are expected in Q4 2009. EHT 0202 has the potential to be the first in a new class of disease modifying Alzheimer's disease therapies that stimulate the ÿ±-secretase pathway and may have neuroprotective and procognitive effects in addition to a symptomatic action.

As part of our repositioning efforts, several proprietary compounds are being evaluated for development in central nervous system and cancer indications.

In January 2009, ExonHit Therapeutics announced the early renewal of its strategic drug discovery collaboration with Allergan. The partnership term was extended until December 2011 and its scope expanded to include epitope discovery in ophthalmology.

As part of this collaboration expansion, ExonHit Therapeutics is further leveraging its technology to investigate a variety of ocular disease related models in order to discover novel epitope targets for the development of therapeutic antibodies.

EHT/AGN 0001, the most advanced compound of the Allergan collaboration, continues to make progress and is ending Phase I clinical testing for pain indications.

    
'/>"/>
SOURCE ExonHit Therapeutics SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. ExonHit is Honoured by the "Innovation Trophy" From The National Institute of Industrial Property (INPI)
2. ExonHit Launches Mouse Genome SpliceArray(TM) for use in Human Disease Modeling Studies
3. Loic Maurel Joins Exonhit Therapeutics to Become CEO
4. ExonHit Launches Rat Genome SpliceArray(TM) Products to Expand High Resolution Gene Expression Profiling for use in Disease Modeling and Toxicogenomics
5. Frederic Desdouits Appointed Member of the Supervisory Board of ExonHit Therapeutics
6. ExonHit Appoints a New Management Board
7. ExonHit Therapeutics - 2007 Financial Results
8. ExonHit Builds A New Organisation
9. ExonHit and bioMerieux Amend Their Strategic Partnership
10. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
11. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... and NEW YORK , ... from its open-label pilot study of mazindol in children ... Development and Therapy in December 2014 . ... mazindol in children with attention deficit/hyperactivity disorder" ( Konofal ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) shows ...
(Date:12/22/2014)... Dec. 22, 2014 GenomeDx Biosciences today announced ... Cancer Classifier, a genomic test for prostate cancer, was ... men managed by radical prostatectomy without adjuvant therapy. Although ... relatively uncommon, using tumor genomics to identify these men ... is an important advance. The study has been ...
(Date:12/19/2014)... PA (PRWEB) December 19, 2014 ... leading developer and manufacturer of needle-free injection technology, ... agreement with Immunomic Therapeutics, Inc. (“ITI”) for ITI ... device with its LAMP™ vaccine platform. , ... an exclusive Worldwide license to the Biojector®-2000 that ...
(Date:12/19/2014)... Bina Technologies, Inc. (Bina, Redwood ... have been acquired by Roche (SIX: RO, ROG; OTCQX: ... company that provides a big data platform for centralized ... for the academic and translational research markets.  Bina will ... continue to focus on development of their innovative genomic ...
Breaking Biology Technology:Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... , , AIX-EN-PROVENCE, France, ... received 510K Clearance from the FDA for its Aixplorer(TM) ultrasound ... in the United States. Aixplorer is the only commercially ... based upon interaction between conventional longitudinal waves and shear waves ...
... CAMBRIDGE, Mass., Aug. 25 Peptimmune, Inc., a ... clinical trial to evaluate the safety, tolerability, pharmacokinetics, and ... Sclerosis (SP-MS). PI-2301 is a novel peptide copolymer ... diseases. , , The Phase Ib ...
... ... An Innovative Treatment for Multiple Sclerosis and Other Autoimmune Diseases , ... New York, NY/Rockville, MD (Vocus) August ... National Multiple Sclerosis Society,s subsidiary devoted to bridging the gap between research and drug ...
Cached Biology Technology:SuperSonic Imagine Receives FDA Approval for Aixplorer Ultrasound System 2SuperSonic Imagine Receives FDA Approval for Aixplorer Ultrasound System 3SuperSonic Imagine Receives FDA Approval for Aixplorer Ultrasound System 4Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009 2Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009 3Fast Forward, LLC and Amplimmune, Inc. Join Forces to Speed New Treatments to People with MS** 2Fast Forward, LLC and Amplimmune, Inc. Join Forces to Speed New Treatments to People with MS** 3Fast Forward, LLC and Amplimmune, Inc. Join Forces to Speed New Treatments to People with MS** 4
(Date:12/17/2014)... DENVER , Dec. 16, 2014  Automation ... is this more evident than at international borders. ... secure document scanners have allowed veteran travelers to ... Automated Passport Control (APC) Kiosks at an increasing ... the globe. According to ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... to their offering. One major ... technology. With continuous advances in technology, it is ... standard that meets the needs and expectations of ...
(Date:12/11/2014)... Dec. 10, 2014  That blood pressure plays a role ... Hypertension – the medical term for high blood pressure – ... and the inflatable cuff that,s used in measuring blood pressure ... there,s nothing new about hypertension, its triggers and its effects. ... the condition and the best ways to treat it. ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... CITY, Aug. 31, 2009 Researchers at Huntsman Cancer Institute ... on Ewing,s sarcoma, an often deadly bone cancer that typically ... with poor outcomes have tumors with high levels of a ... chemotherapy. The research is published online today in the journal ...
... its usefulness in counting copies of duplicated genome sequences and ... study to be published Aug. 30 in Nature Genetics ... differ from one person to the next. The researchers ... Search Tool. The study is titled, "Personalized Copy Number and ...
... on the neural mechanisms involved in social behavior, neuroscientists ... the brain structure responsible for our sense of personal ... 30 issue of the journal Nature Neuroscience , ... social distance is an issue. The structure, the ...
Cached Biology News:New hope for deadly childhood bone cancer 2Counting duplicated genome segments now possible 2Counting duplicated genome segments now possible 3Caltech neuroscientists find brain region responsible for our sense of personal space 2Caltech neuroscientists find brain region responsible for our sense of personal space 3Caltech neuroscientists find brain region responsible for our sense of personal space 4
Rabbit polyclonal antibody to NMDA NR2B [Tyr1336]...
... Reagent A: MTT, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide), ... that is cleaved by living cells to ... process requires active mitochondria, and even freshly ... of MTT. Reagent A is a component ...
Mouse polyclonal antibody to ALS2CR8 - amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 8...
Determin interaction of your protein with Echelons lipids...
Biology Products: